Title :

Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.

Author(s) :

Cornu, Marjorie [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Bruno, Benedicte [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Loridant, Severine [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995
Lille Inflammation Research International Center - U 995 [LIRIC]
Navarin, Pauline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Francois, Nadine [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lanternier, Fanny [Auteur]
Centre d'infectiologie Necker-Pasteur [CHU Necker]
Amzallag-Bellenger, Elisa [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dubos, Francois [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Mazingue, Francoise [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Sendid, Boualem [Auteur]
Lille Inflammation Research International Center (LIRIC) - U995
Lille Inflammation Research International Center - U 995 [LIRIC]

Journal title :

BMC pharmacology & toxicology

Abbreviated title :

BMC Pharmacol Toxicol

Volume number :

19

Pages :

81

Publication date :

2018-12-06

ISSN :

2050-6511

English keyword(s) :

Isavuconazole
Mucormycosis
Paediatrics
Drug-monitoring
Lichtheimia

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date. Very few paediatric cases ...
Show more >BACKGROUND: The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date. Very few paediatric cases have been published concerning the use of isavuconazole. Amphotericin B is the only antifungal agent recommended in paediatric mucormycosis, but adverse effects and especially nephrotoxicity, even with the liposomal formulation, could be problematic. In this context, the use of other antifungal molecules active on Mucorales becomes needful. METHODS: We describe a case of mucormycosis with rapid onset dissemination in a 3-year-old girl recently diagnosed with acute lymphocytic leukaemia. She was successfully treated with isavuconazole alone and then in combination with liposomal amphotericin B. Isavuconazole therapy was guided by therapeutic drug monitoring. CONCLUSIONS: This case offers new perspectives on the potential use of isavuconazole in children with mucormycosis, as an alternative or adjunct to liposomal amphotericin B.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-10-22T14:20:52Z
2020-03-20T16:48:36Z